Back Article

Figure 1. 

Schematic diagram illustrating the ceramide-CYSLTR2/P2RY6 pathway in atherosclerosis and its therapeutic implication. Ceramide-mediated activation of receptors CYSLTR2 and P2RY6 recruits Gq protein, leading to downstream inflammasome activation and promoting atherosclerotic plaque formation. Inhibiting CYSLTR2 and P2RY6 represents a novel strategy to reduce atherosclerotic plaque burden independently of blood lipid levels.